SG Americas Securities LLC Sells 155,769 Shares of Bristol Myers Squibb Company $BMY

SG Americas Securities LLC lessened its position in shares of Bristol Myers Squibb Company (NYSE:BMY) by 23.9% in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 496,918 shares of the biopharmaceutical company’s stock after selling 155,769 shares during the period. SG Americas Securities LLC’s holdings in Bristol Myers Squibb were worth $23,002,000 at the end of the most recent quarter.

Several other hedge funds have also added to or reduced their stakes in the company. Brighton Jones LLC increased its position in Bristol Myers Squibb by 33.4% during the 4th quarter. Brighton Jones LLC now owns 19,728 shares of the biopharmaceutical company’s stock worth $1,116,000 after buying an additional 4,935 shares during the period. Massachusetts Financial Services Co. MA bought a new position in Bristol Myers Squibb during the first quarter worth about $2,298,000. Bailard Inc. increased its position in Bristol Myers Squibb by 25.9% during the first quarter. Bailard Inc. now owns 7,160 shares of the biopharmaceutical company’s stock worth $437,000 after acquiring an additional 1,472 shares during the period. Nwam LLC raised its stake in Bristol Myers Squibb by 10.7% in the 1st quarter. Nwam LLC now owns 20,458 shares of the biopharmaceutical company’s stock worth $1,248,000 after purchasing an additional 1,985 shares in the last quarter. Finally, St. Louis Trust Co grew its position in shares of Bristol Myers Squibb by 11.6% during the 1st quarter. St. Louis Trust Co now owns 33,158 shares of the biopharmaceutical company’s stock worth $2,022,000 after purchasing an additional 3,451 shares in the last quarter. 76.41% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on BMY. Wall Street Zen upgraded Bristol Myers Squibb from a “buy” rating to a “strong-buy” rating in a research note on Saturday, November 8th. Citigroup reaffirmed a “neutral” rating on shares of Bristol Myers Squibb in a report on Monday, October 13th. Daiwa Capital Markets cut Bristol Myers Squibb from an “outperform” rating to a “neutral” rating and set a $42.00 price target on the stock. in a research report on Tuesday, August 5th. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Bristol Myers Squibb in a research report on Tuesday, October 14th. Finally, Daiwa America lowered shares of Bristol Myers Squibb from a “strong-buy” rating to a “hold” rating in a report on Tuesday, August 5th. Four investment analysts have rated the stock with a Buy rating and fourteen have given a Hold rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $54.58.

Insider Buying and Selling

In other Bristol Myers Squibb news, EVP David V. Elkins sold 56,000 shares of the stock in a transaction dated Tuesday, September 2nd. The stock was sold at an average price of $47.33, for a total value of $2,650,480.00. Following the completion of the transaction, the executive vice president directly owned 167,379 shares in the company, valued at approximately $7,922,048.07. This trade represents a 25.07% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 0.09% of the company’s stock.

Bristol Myers Squibb Stock Down 4.0%

Shares of NYSE BMY opened at $46.67 on Friday. The company has a market cap of $95.00 billion, a price-to-earnings ratio of 18.82, a PEG ratio of 2.23 and a beta of 0.33. The company has a current ratio of 1.21, a quick ratio of 1.11 and a debt-to-equity ratio of 2.54. Bristol Myers Squibb Company has a 12 month low of $42.52 and a 12 month high of $63.33. The stock has a 50-day moving average price of $45.34 and a two-hundred day moving average price of $46.68.

Bristol Myers Squibb (NYSE:BMY) last announced its quarterly earnings results on Thursday, October 30th. The biopharmaceutical company reported $1.63 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.52 by $0.11. The company had revenue of $12.22 billion for the quarter, compared to analyst estimates of $11.75 billion. Bristol Myers Squibb had a net margin of 10.58% and a return on equity of 80.04%. The firm’s revenue was up 2.8% on a year-over-year basis. During the same period in the previous year, the firm posted $1.80 EPS. Bristol Myers Squibb has set its FY 2025 guidance at 6.400-6.600 EPS. As a group, analysts forecast that Bristol Myers Squibb Company will post 6.74 earnings per share for the current fiscal year.

Bristol Myers Squibb Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Monday, November 3rd. Investors of record on Friday, October 3rd were given a dividend of $0.62 per share. The ex-dividend date was Friday, October 3rd. This represents a $2.48 dividend on an annualized basis and a yield of 5.3%. Bristol Myers Squibb’s payout ratio is currently 83.78%.

Bristol Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.